Overview

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Status:
RECRUITING
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Jiaolian Drug Research and Development Co., Ltd
Collaborator:
Shanghai Pharmaceuticals Holding Co., Ltd
Treatments:
Paclitaxel